The effect on survival of initial chemotherapy in advanced breast cancer

Polychemotherapy versus single drug

D. L. Ahmann, Daniel J Schaid, H. F. Bisel, R. G. Hahn, J. H. Edmonson, J. N. Ingle

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Since current clinical trials assessing new agents occur in patients with advanced breast cancer having failed one and sometimes many polychemotherapy programs, these new agents may not be given a fair trial. In an effort to assess the possibility of using an alternative study design, we analyzed older clinical trials that used a controlled study design, randomizing between a single new drug and an established polychemotherapy program with a cross-over design upon failure. We were interested in noting that the pooled data did display a slight survival advantage (median 3.7 months) for the group receiving polychemotherapy as initial therapy. The survival distributions were clearly not significant using the log rank test, but did approach significance using the Smirnov. It is apparent that, while some slight advantage does occur for that group of patients receiving initial polychemotherapy, the magnitude of this effect is not great and is short in duration. Serious consideration should be given to the assessment of new agents as first-line therapy, particularly should they have a unique mode of action or lessened morbidities or toxicities.

Original languageEnglish (US)
Pages (from-to)1928-1932
Number of pages5
JournalJournal of Clinical Oncology
Volume5
Issue number12
StatePublished - 1987

Fingerprint

Combination Drug Therapy
Breast Neoplasms
Drug Therapy
Survival
Pharmaceutical Preparations
Clinical Trials
Data Display
Cross-Over Studies
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ahmann, D. L., Schaid, D. J., Bisel, H. F., Hahn, R. G., Edmonson, J. H., & Ingle, J. N. (1987). The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. Journal of Clinical Oncology, 5(12), 1928-1932.

The effect on survival of initial chemotherapy in advanced breast cancer : Polychemotherapy versus single drug. / Ahmann, D. L.; Schaid, Daniel J; Bisel, H. F.; Hahn, R. G.; Edmonson, J. H.; Ingle, J. N.

In: Journal of Clinical Oncology, Vol. 5, No. 12, 1987, p. 1928-1932.

Research output: Contribution to journalArticle

Ahmann, DL, Schaid, DJ, Bisel, HF, Hahn, RG, Edmonson, JH & Ingle, JN 1987, 'The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug', Journal of Clinical Oncology, vol. 5, no. 12, pp. 1928-1932.
Ahmann, D. L. ; Schaid, Daniel J ; Bisel, H. F. ; Hahn, R. G. ; Edmonson, J. H. ; Ingle, J. N. / The effect on survival of initial chemotherapy in advanced breast cancer : Polychemotherapy versus single drug. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 12. pp. 1928-1932.
@article{f119def08ce94c4aacb9262b27de7c99,
title = "The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug",
abstract = "Since current clinical trials assessing new agents occur in patients with advanced breast cancer having failed one and sometimes many polychemotherapy programs, these new agents may not be given a fair trial. In an effort to assess the possibility of using an alternative study design, we analyzed older clinical trials that used a controlled study design, randomizing between a single new drug and an established polychemotherapy program with a cross-over design upon failure. We were interested in noting that the pooled data did display a slight survival advantage (median 3.7 months) for the group receiving polychemotherapy as initial therapy. The survival distributions were clearly not significant using the log rank test, but did approach significance using the Smirnov. It is apparent that, while some slight advantage does occur for that group of patients receiving initial polychemotherapy, the magnitude of this effect is not great and is short in duration. Serious consideration should be given to the assessment of new agents as first-line therapy, particularly should they have a unique mode of action or lessened morbidities or toxicities.",
author = "Ahmann, {D. L.} and Schaid, {Daniel J} and Bisel, {H. F.} and Hahn, {R. G.} and Edmonson, {J. H.} and Ingle, {J. N.}",
year = "1987",
language = "English (US)",
volume = "5",
pages = "1928--1932",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - The effect on survival of initial chemotherapy in advanced breast cancer

T2 - Polychemotherapy versus single drug

AU - Ahmann, D. L.

AU - Schaid, Daniel J

AU - Bisel, H. F.

AU - Hahn, R. G.

AU - Edmonson, J. H.

AU - Ingle, J. N.

PY - 1987

Y1 - 1987

N2 - Since current clinical trials assessing new agents occur in patients with advanced breast cancer having failed one and sometimes many polychemotherapy programs, these new agents may not be given a fair trial. In an effort to assess the possibility of using an alternative study design, we analyzed older clinical trials that used a controlled study design, randomizing between a single new drug and an established polychemotherapy program with a cross-over design upon failure. We were interested in noting that the pooled data did display a slight survival advantage (median 3.7 months) for the group receiving polychemotherapy as initial therapy. The survival distributions were clearly not significant using the log rank test, but did approach significance using the Smirnov. It is apparent that, while some slight advantage does occur for that group of patients receiving initial polychemotherapy, the magnitude of this effect is not great and is short in duration. Serious consideration should be given to the assessment of new agents as first-line therapy, particularly should they have a unique mode of action or lessened morbidities or toxicities.

AB - Since current clinical trials assessing new agents occur in patients with advanced breast cancer having failed one and sometimes many polychemotherapy programs, these new agents may not be given a fair trial. In an effort to assess the possibility of using an alternative study design, we analyzed older clinical trials that used a controlled study design, randomizing between a single new drug and an established polychemotherapy program with a cross-over design upon failure. We were interested in noting that the pooled data did display a slight survival advantage (median 3.7 months) for the group receiving polychemotherapy as initial therapy. The survival distributions were clearly not significant using the log rank test, but did approach significance using the Smirnov. It is apparent that, while some slight advantage does occur for that group of patients receiving initial polychemotherapy, the magnitude of this effect is not great and is short in duration. Serious consideration should be given to the assessment of new agents as first-line therapy, particularly should they have a unique mode of action or lessened morbidities or toxicities.

UR - http://www.scopus.com/inward/record.url?scp=0023514431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023514431&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 1928

EP - 1932

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -